CN100335492C - 生产3’－核苷前体药物的方法 - Google Patents

生产3’－核苷前体药物的方法 Download PDF

Info

Publication number
CN100335492C
CN100335492C CNB2003801098204A CN200380109820A CN100335492C CN 100335492 C CN100335492 C CN 100335492C CN B2003801098204 A CNB2003801098204 A CN B2003801098204A CN 200380109820 A CN200380109820 A CN 200380109820A CN 100335492 C CN100335492 C CN 100335492C
Authority
CN
China
Prior art keywords
situation
occur
under
nucleosides
optional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2003801098204A
Other languages
English (en)
Chinese (zh)
Other versions
CN1751058A (zh
Inventor
理查德·斯托勒
阿德尔·穆萨
史蒂文·马蒂厄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idenix Cayman Ltd
Original Assignee
Idenix Cayman Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idenix Cayman Ltd filed Critical Idenix Cayman Ltd
Publication of CN1751058A publication Critical patent/CN1751058A/zh
Application granted granted Critical
Publication of CN100335492C publication Critical patent/CN100335492C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CNB2003801098204A 2002-12-23 2003-12-23 生产3’－核苷前体药物的方法 Expired - Fee Related CN100335492C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43615002P 2002-12-23 2002-12-23
US60/436,150 2002-12-23

Publications (2)

Publication Number Publication Date
CN1751058A CN1751058A (zh) 2006-03-22
CN100335492C true CN100335492C (zh) 2007-09-05

Family

ID=32682350

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2003801098204A Expired - Fee Related CN100335492C (zh) 2002-12-23 2003-12-23 生产3’－核苷前体药物的方法

Country Status (16)

Country Link
US (1) US20040181051A1 (enExample)
EP (1) EP1575971A4 (enExample)
JP (1) JP2006514038A (enExample)
KR (1) KR20050110611A (enExample)
CN (1) CN100335492C (enExample)
AU (1) AU2003300434A1 (enExample)
BR (1) BR0316868A (enExample)
CA (1) CA2511616A1 (enExample)
IL (1) IL169314A0 (enExample)
MX (1) MXPA05006865A (enExample)
NO (1) NO20053557L (enExample)
NZ (1) NZ540913A (enExample)
PL (1) PL377608A1 (enExample)
RU (1) RU2005123395A (enExample)
WO (1) WO2004058792A1 (enExample)
ZA (1) ZA200505040B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CZ301182B6 (cs) 2000-05-26 2009-12-02 Idenix (Cayman) Limited Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
MXPA04012802A (es) 2002-06-28 2005-04-19 Idenix Cayman Ltd Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
WO2004046331A2 (en) 2002-11-15 2004-06-03 Idenix (Cayman) Limited 2’-branched nucleosides and flaviviridae mutation
US7598373B2 (en) 2002-12-12 2009-10-06 Idenix Pharmaceuticals, Inc. Process for the production of 2-C-methyl-D-ribonolactone
CN1812995A (zh) * 2003-04-28 2006-08-02 艾登尼科斯（开曼）有限公司 工业化规模的核苷合成
EP1758453B1 (en) * 2004-06-15 2014-07-16 Merck Sharp & Dohme Corp. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
AU2005302448B2 (en) * 2004-10-29 2012-07-19 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
KR20070087624A (ko) * 2004-12-23 2007-08-28 노파르티스 아게 Ｈｃｖ 치료용 조성물
AU2006222563A1 (en) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
EP2537520A1 (en) 2005-03-29 2012-12-26 Biocryst Pharmaceuticals, Inc. Hepatics C therapies
JP4885963B2 (ja) * 2005-09-22 2012-02-29 エフ．ホフマン−ラ ロシュ アーゲー ヌクレオシドの選択的ｏ−アシル化
EP1987050A2 (en) * 2006-02-14 2008-11-05 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
WO2007113159A1 (en) 2006-04-04 2007-10-11 F. Hoffmann-La Roche Ag 3',5'-di-o-acylated nucleosides for hcv treatment
WO2010015637A1 (en) * 2008-08-06 2010-02-11 Novartis Ag New antiviral modified nucleosides
CN102695513A (zh) 2008-12-23 2012-09-26 吉利德制药有限责任公司 核苷氨基磷酸酯
AU2009329917B2 (en) 2008-12-23 2016-03-31 Gilead Pharmasset Llc Nucleoside analogs
BRPI0923815A2 (pt) 2008-12-23 2015-07-14 Pharmasset Inc Síntese de nucleosídeos de purina
JP2012514657A (ja) 2009-01-09 2012-06-28 ユニバーシテイ・カレツジ・オブ・カーデイフ・コンサルタンツ・リミテツド ウィルス感染を治療するためのグアノシンヌクレオシド化合物のホスホルアミダート誘導体
SMT201700412T1 (it) 2010-03-31 2017-11-15 Gilead Pharmasset Llc Procedimento per la cristallizzazione di (s)-isopropil 2-(((s)-(perfluorofenossi)(fenossi)fosforil)ammino)propanoato
EP3512863B1 (en) 2016-09-07 2021-12-08 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
MX2021006121A (es) * 2018-11-25 2021-10-13 Tnt Medical Corp Profarmaco de gemcitabina oralmente activo.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090121A2 (en) * 2000-05-23 2001-11-29 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus
WO2001092282A2 (en) * 2000-05-26 2001-12-06 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
USRE29835E (en) * 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
FR2562543B1 (fr) * 1984-04-10 1987-09-25 Elf Aquitaine Nouveaux phosphonites cycliques, leur preparation et applications
NL8403224A (nl) * 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
CA2083961A1 (en) * 1990-05-29 1991-11-30 Henk Van Den Bosch Synthesis of glycerol di- and triphosphate derivatives
US5627165A (en) * 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US5543389A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5256641A (en) * 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5157027A (en) * 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US5696277A (en) * 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
CA2267279A1 (en) * 1996-10-16 1998-04-23 Devron Averett Monocyclic l-nucleosides, analogs and uses thereof
US6248878B1 (en) * 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
KR100954390B1 (ko) * 1998-02-25 2010-04-26 에모리 유니버시티 2'-플루오로뉴클레오사이드
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
TR200003635T2 (tr) * 1998-06-08 2001-04-20 F.Hoffmann-La Roche Ag Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.
US6752981B1 (en) * 1999-09-08 2004-06-22 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
WO2001032153A2 (en) * 1999-11-04 2001-05-10 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
CA2396713A1 (en) * 1999-12-22 2001-07-05 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
US6495677B1 (en) * 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
SK11922002A3 (sk) * 2000-02-18 2003-06-03 Shire Biochem Inc. Použitie analógov nukleozidov na liečenie alebo prevenciu infekcií spôsobených flavivírusom
JP2003532643A (ja) * 2000-04-13 2003-11-05 フアーマセツト・リミテツド 肝炎ウイルス感染症を治療するための３’−または２’−ヒドロキシメチル置換ヌクレオシド誘導体
WO2001081359A1 (en) * 2000-04-20 2001-11-01 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
NZ575481A (en) * 2000-10-18 2010-10-29 Pharmasset Inc Simultaneous quantification of nucleic acids in diseased cells
HK1052878A1 (zh) * 2000-10-18 2003-10-03 Schering Corporation 利巴传林-聚乙二醇化干扰素α：丙型肝炎病毒的联合治疗
DK2251015T3 (da) * 2000-10-18 2013-05-13 Gilead Pharmasset Llc Modificerede nukleotider til behandling af virusinfektioner og abnorm celleproliferation
US7105499B2 (en) * 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
SK286630B6 (sk) * 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
GB0112617D0 (en) * 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
WO2003024461A1 (en) * 2001-09-20 2003-03-27 Schering Corporation Hcv combination therapy
US20040002476A1 (en) * 2002-02-14 2004-01-01 Stuyver Lieven J. Modified fluorinated nucleoside analogues
RU2004128943A (ru) * 2002-02-28 2005-04-20 Байота, Инк. (Us) Средства, имитирующие нуклеотиды, и их пролекарственные формы
US7247621B2 (en) * 2002-04-30 2007-07-24 Valeant Research & Development Antiviral phosphonate compounds and methods therefor
CA2484921A1 (en) * 2002-05-06 2003-11-13 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
MXPA04012802A (es) * 2002-06-28 2005-04-19 Idenix Cayman Ltd Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
AU2003263412A1 (en) * 2002-06-28 2004-01-19 Centre National De La Recherche Scientifique (Cnrs) 1'-, 2'- and 3'- modified nucleoside derivatives for treating flaviviridae infections
EP1572097A4 (en) * 2002-09-30 2010-02-17 Smithkline Beecham Corp NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF INFECTIONS WITH THE HEPATITIS C-VIRUS
US7094768B2 (en) * 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
WO2004046331A2 (en) * 2002-11-15 2004-06-03 Idenix (Cayman) Limited 2’-branched nucleosides and flaviviridae mutation
TWI332507B (en) * 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
US7598373B2 (en) * 2002-12-12 2009-10-06 Idenix Pharmaceuticals, Inc. Process for the production of 2-C-methyl-D-ribonolactone

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090121A2 (en) * 2000-05-23 2001-11-29 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus
WO2001092282A2 (en) * 2000-05-26 2001-12-06 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
2'-C-Branched...... Tang et al,J.ORG.CHEM,Vol.64 No.3 1999 *
structure and total synthesis...... Jinping McComick et al,J.AM.CHEM.SOC,Vol.121 1999 *

Also Published As

Publication number Publication date
RU2005123395A (ru) 2006-01-27
CA2511616A1 (en) 2004-07-15
WO2004058792A1 (en) 2004-07-15
EP1575971A4 (en) 2008-03-05
KR20050110611A (ko) 2005-11-23
ZA200505040B (en) 2006-04-26
NO20053557L (no) 2005-09-08
CN1751058A (zh) 2006-03-22
AU2003300434A1 (en) 2004-07-22
MXPA05006865A (es) 2005-12-12
JP2006514038A (ja) 2006-04-27
BR0316868A (pt) 2005-10-25
NZ540913A (en) 2008-02-29
US20040181051A1 (en) 2004-09-16
IL169314A0 (en) 2007-07-04
PL377608A1 (pl) 2006-02-06
EP1575971A1 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
CN100335492C (zh) 生产3’－核苷前体药物的方法
US7582748B2 (en) Methods of manufacture of 2′-deoxy-β-L-nucleosides
US8716263B2 (en) Synthesis of purine nucleosides
US20080139802A1 (en) Preparation of nucleosides ribofuranosyl pyrimidines
CN1374966A (zh) 嘌呤衍生物
CN1311630A (zh) 具有双环糖部分的新核苷类
CN1033183A (zh) 氟胞嘧啶核苷衍生物
SG172921A1 (en) Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
CN1809582A (zh) 制备4＇－叠氮基核苷衍生物的方法
CN1119869A (zh) N-烷基-2-取代的atp类似物
CN1358192A (zh) 嘌呤衍生物
CN1240380C (zh) 吲哚并吡咯并咔唑的相转移催化苷化方法
CN101861320A (zh) 制备卡培他滨以及其中所用的富含β-端基异构体的三烷基碳酸酯化合物的方法
CN1571792A (zh) 2＇－卤代－β－L－阿拉伯呋喃糖基核苷的制备方法
CN1269801A (zh) 作为抗病毒剂的嘌呤非环核苷
CN101066981A (zh) 非环核苷膦酸酯类化合物及其组合物、制备方法和用途
CN1047781C (zh) 制备3'－叠氮基－3'－脱氧胸苷及其衍生物的方法
CN1812995A (zh) 工业化规模的核苷合成
RU2441876C2 (ru) Производное 3'-этинилцитидина
CN88100826A (zh) 核苷酸类似物的生产及其使用
JP4885963B2 (ja) ヌクレオシドの選択的ｏ−アシル化
CN1891710A (zh) L－核苷的前体药物
US20050080252A1 (en) Process for preparing antiviral nucleoside derivatives
HK1064053B (en) Process for phase transfer catalyzed glycosidation of an indolopyrrolocarbazole

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee